| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Escitalopram Oxalate (Cipralex; Lexapro; Lu10171; Lu-10171; Citalopram;Cytalopram), the oxalate salt of Escitalopram which is an approved antidepressant drug, is a potent and selective serotonin (5-HT) reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram Oxalate is the citalopram S-(+)-enantiomer. It has the ability to block [3H]-5-HT uptake and [125I]-RTI-55 binding in COS-1 cells that express the 5-HTT human serotonin transporter, with Ki values of 3.9±2.2nM and 6.6±1.4nM, respectively.
| Targets |
serotonin transporter ( Ki = 0.89 nM ); DAT ( Ki = 10500 nM ); NET ( Ki = 8150 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Animal Protocol |
Male Sprague-Dawley rats
10 mg/kg I.p.; daily for 28 days |
|
| References |
| Molecular Formula |
C22H23FN2O5
|
|
|---|---|---|
| Molecular Weight |
414.43
|
|
| Exact Mass |
414.16
|
|
| Elemental Analysis |
C, 63.76; H, 5.59; F, 4.58; N, 6.76; O, 19.30
|
|
| CAS # |
219861-08-2
|
|
| Related CAS # |
Escitalopram; 128196-01-0; Escitalopram-d6 oxalate; 1217733-09-9; Escitalopram-d4 oxalate
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
|
|
| InChi Key |
KTGRHKOEFSJQNS-BDQAORGHSA-N
|
|
| InChi Code |
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m0./s1
|
|
| Chemical Name |
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 100 mg/mL (241.30 mM) (saturation unknown) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4130 mL | 12.0648 mL | 24.1295 mL | |
| 5 mM | 0.4826 mL | 2.4130 mL | 4.8259 mL | |
| 10 mM | 0.2413 mL | 1.2065 mL | 2.4130 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04497168 | Active Recruiting |
Drug: Citalopram 20mg Drug: Placebo |
Parkinson Disease | University of Michigan | April 1, 2021 | Phase 2 |
| NCT04846829 | Active Recruiting |
Drug: Placebo Drug: intravenous citalopram hydrochloride (CIT) |
Major Depressive Disorder | University of California, Los Angeles |
April 24, 2017 | Early Phase 1 |
| NCT02553161 | Active Recruiting |
Drug: Escitalopram Behavioral: Cognitive behavioral Psychotherapy |
Depression Anxiety Bipolar Disorder |
University of Cincinnati | December 2015 | Not Applicable |
| NCT00667121 | Active Recruiting |
Drug: gabapentin Drug: venlafaxine Drug: tamoxifen citrate |
Breast Cancer Depression Hot Flashes |
Mayo Clinic | March 16, 2011 | N/A |
| NCT03108846 | Recruiting | Drug: Escitalopram Drug: Placebo |
Dementia | JHSPH Center for Clinical Trials |
January 3, 2018 | Phase 3 |
 |
|---|
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA